Equities

Alvotech SA

Alvotech SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.02
  • Today's Change-0.42 / -3.38%
  • Shares traded56.02k
  • 1 Year change+31.73%
  • Beta-0.1145
Data delayed at least 15 minutes, as of Nov 22 2024 20:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2024202420232022
ASSETS
Cash And Short Term Investments1181166
Total Receivables, Net1468771
Total Inventory1257471
Prepaid expenses--2221
Other current assets, total44--0.85
Total current assets433195231
Property, plant & equipment, net409357268
Goodwill, net121212
Intangibles, net211926
Long term investments--1849
Note receivable - long term29113.29
Other long term assets9.522.245.78
Total assets1,233950828
LIABILITIES
Accounts payable588149
Accrued expenses--6354
Notes payable/short-term debt--00
Current portion long-term debt/capital leases344825
Other current liabilities, total697039
Total current liabilities161261167
Total long term debt--1,028780
Total debt1,1811,075805
Deferred income tax1.540.050.31
Minority interest------
Other liabilities, total268594445
Total liabilities1,5771,8831,393
SHAREHOLDERS EQUITY
Common stock2.832.282.13
Additional paid-in capital2,0081,2301,058
Retained earnings (accumulated deficit)(2354)(2163)(1624)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.18)(1.53)(1.44)
Total equity(344)(932)(564)
Total liabilities & shareholders' equity1,233950828
Total common shares outstanding--267252
Treasury shares - common primary issue--00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.